Solrun Melkorka Maggadottir

  • PhD student; MD

HELSE SØR ØST

Education:

2017-to date: PhD student at the Department of Cellular Therapy/Faculty of Medicine University of Oslo, Norway.

2011-2014: Board Certified Allergist and Immunologist, University of Pennsylvania (UPENN), PA, USA. ”

2008-2011: Board Certified Pediatrician, University of Connecticut, Hartford, CT, USA.

1999-2005: MD, University of Iceland, Reykjavik, Iceland.

 

Research interests/projects:

Development and clinical implementation of novel immunotherapies

    • Translation/transition of pre-clinical data into clinical trials with focus on safety and efficacy
    • Therapeutic TCR (T Cell Receptor) discovery, validation and translation into clinical trials
    • Therapeutic CAR (Chimeric Antigen Receptor) discovery, validation and translation into clinical trials
    • Improvement and advancement of clinical trials in cell-based therapy

Work experience

2017-to date:   PhD student, Department of Cellular Therapy, OUS-Radiumhospitalet, Norway

2014-2016:     Immunology Specialist MD at the Department of Immunology, LSH University Hospital, Iceland.

2011-2014:     Fellowship in Allergy/Immunology, The Children’s Hospital of Philadelphia, PA, USA

2008-2011:     Pediatric Internship/Residency, Connecticut Children’s Medical Center, CT, USA 

2006-2008:     Critical Care/Anesthesiology and Pediatric Resident, LSH University Hospital, Iceland

2005-2006:     Rotating Internship in Medicine, Surgery and Pediatrics, Landspitali (LSH) University Hospital, Iceland

Awards

  • Oral presentation at AAAAI was selected as one of 9 abstracts from >1000 abstracts to be discussed at one of three press events during the meeting.
  • Travel awards from AAAAI: 2011, 2013 and 2014. ACAAI: 2012 and 2013. ESID: 2012 and CIS: 2014.
  • “Outstanding intern award” in pediatric residency in Connecticut, 2009.
  • “Best research project of the year” in medical school, 2003.
 

Publications 2024

Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Hønnåshagen TK, Sæbøe-Larssen S, Josefsen D, Hagtvedt T, Wälchli S, Kvalheim G, Inderberg EM (2024)
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer
32 (6), 2021-2029
DOI 10.1016/j.ymthe.2024.04.009, PubMed 38582964

Publications 2023

Mensali N, Köksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fåne A, Ramírez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland ØS, Menendez P et al. (2023)
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
14 (1), 3375
DOI 10.1038/s41467-023-39097-x, PubMed 37291203

Publications 2022

Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
12, 1031232
DOI 10.3389/fonc.2022.1031232, PubMed 36439452

Publications 2020

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301

Publications 2019

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Publications 2015

Li J, Jørgensen SF, Maggadottir SM, Bakay M, Warnatz K, Glessner J, Pandey R, Salzer U, Schmidt RE, Perez E, Resnick E, Goldacker S, Buchta M, Witte T, Padyukov L, Videm V, Folseraas T, Atschekzei F, Elder JT, Nair RP, Winkelmann J, Gieger C, Nöthen MM, Büning C, Brand S et al. (2015)
Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells
6, 6804
DOI 10.1038/ncomms7804, PubMed 25891430

Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, Hou C, Abrams DJ, Chang D, Gao F, Guo Y, Wei Z, Connolly JJ, Cardinale CJ, Bakay M, Glessner JT, Li D, Kao C, Thomas KA, Qiu H, Chiavacci RM, Kim CE, Wang F, Snyder J, Richie MD et al. (2015)
Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases
21 (9), 1018-27
DOI 10.1038/nm.3933, PubMed 26301688

Li YR, Zhao SD, Li J, Bradfield JP, Mohebnasab M, Steel L, Kobie J, Abrams DJ, Mentch FD, Glessner JT, Guo Y, Wei Z, Connolly JJ, Cardinale CJ, Bakay M, Li D, Maggadottir SM, Thomas KA, Qui H, Chiavacci RM, Kim CE, Wang F, Snyder J, Flatø B, Førre Ø et al. (2015)
Genetic sharing and heritability of paediatric age of onset autoimmune diseases
6, 8442
DOI 10.1038/ncomms9442, PubMed 26450413

Maggadottir SM, Li J, Glessner JT, Li YR, Wei Z, Chang X, Mentch FD, Thomas KA, Kim CE, Zhao Y, Hou C, Wang F, Jørgensen SF, Perez EE, Sullivan KE, Orange JS, Karlsen TH, Chapel H, Cunningham-Rundles C, Hakonarson H (2015)
Rare variants at 16p11.2 are associated with common variable immunodeficiency
135 (6), 1569-77
DOI 10.1016/j.jaci.2014.12.1939, PubMed 25678086

Scroll to top